Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 26, 2021 12:28 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard1 (“LNP-mRNA”) delivered...
August 24, 2021 10:44 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University

MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
August 23, 2021 15:52 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel

Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).Sofusa is a revolutionary technology which delivers biologic...
August 19, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido®...
August 09, 2021 14:39 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
August 04, 2021 12:57 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), in collaboration with The Scripps Research Institute of La Jolla, today announced that the...
July 20, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter

China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
January 26, 2021 19:09 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse events noted for any patient treated to date SAN DIEGO, Jan. 26, 2021 ...
January 10, 2021 17:58 ET | Source: Sorrento Therapeutics, Inc.

Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference

SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
November 29, 2020 20:19 ET | Source: Sorrento Therapeutics, Inc.

Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference

SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper...

Next Page keyboard_arrow_right